Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 12/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30573038 | 0.82 | HTR2C (0.56) | MRGPRX4FFAR4HTR2CSLC6A4HTR2B | |
| SCHEMBL12167392 | 0.82 | HTR2C (0.56) | MRGPRX4FFAR4HTR2CSLC6A4HTR2B | |
| SCHEMBL24726468 | 0.77 | MAOB (0.48) | MRGPRX4FFAR4MAOBIDO1 | |
| SCHEMBL23135657 | 0.76 | MRGPRX4 (0.68) | MRGPRX4 | |
| SCHEMBL19237512 | 0.76 | MRGPRX4 (0.52) | MRGPRX4FFAR4MAOBIDO1HTR2C | |
| SCHEMBL12330828 | 0.75 | FFAR4 (0.60) | MRGPRX4FFAR4MAOBIDO1SLC6A4 | |
| SCHEMBL19237551 | 0.75 | MRGPRX4 (0.51) | MRGPRX4FFAR4MAOBIDO1HTR2C | |
| SCHEMBL14200042 | 0.75 | KEAP1 (0.53) | — | |
| SCHEMBL22470002 | 0.74 | MRGPRX4 (1.00) | MRGPRX4 | |
| SCHEMBL31568422 | 0.74 | MRGPRX4 (1.00) | MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | MRGPRX4 243/4885FFAR4 1371/4885MAOB 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.